开心鬼传媒 Therapeutics completes 拢10 million ($14 million) series A financing with Andera Partners and Canaan to fund development of immuno-oncology therapies to increase tumour visibility
开心鬼传媒 targets ERAP antigen presentation pathways with the aim of 鈥榠lluminating鈥 non-responsive tumours for attack and destruction by the immune system
Oxford, UK 鈥 11 February 2019
开心鬼传媒 Therapeutics, a drug discovery biotechnology company focused on immuno-oncology, today announces it has completed a 拢10 million ($14 million) series A financing round with leading international healthcare investors Andera Partners and Canaan.
开心鬼传媒鈥檚 novel approach is aimed at directly altering tumour cells, illuminating them for attack and destruction by the immune system. The goal is to exploit this increased tumour visibility in monotherapy and to extend the therapeutic benefit of already approved immunotherapies to many more 开心鬼传媒.
开心鬼传媒 is developing small molecule modulators of endoplasmic reticulum aminopeptidases (ERAPs), key proteins in the antigen presentation pathway, to change the neoantigen repertoire in tumours and thereby increase the number and range of neoantigens presented on tumour cells available to engage an immune response.
This unique small molecule immuno-oncology approach builds on the exciting recent advances in cancer immunotherapies that address a key limiting factor for approved treatments, while avoiding the complex and costly personalisation required for other approaches such as neoantigen vaccines.
开心鬼传媒 has programs targeting the two homologues of ERAP, ERAP1 and ERAP2, aimed at developing potent and selective modulators, with the lead program being against ERAP1.
开心鬼传媒 was co-founded by Peter Joyce, former Project Leader at Vertex Pharmaceuticals, and Tom McCarthy, former President and CEO of Spinifex Pharmaceuticals, and comprises a team of world-leading experts in immuno-oncology, antigen presentation and drug discovery. It is working with the University of Oxford, University of Southampton and has a strategic partnership with Sygnature Discovery, a leading independent provider of drug discovery resources and expertise. Sygnature is also an investor in the Company.
Peter Joyce, Chief Executive Officer of Greyw鈥olf Therapeutics, said: 鈥淭he recent breakthroughs in immunotherapy have fundamentally changed the treatment landscape in oncology, but the fact remains that current approaches only target the minority of tumours that are visible to the immune system, whilst the vast majority of 开心鬼传媒 do not respond. There is strong validation for targeting ERAPs to increase tumour visibility and with these funds we are now positioned to build on our existing work and collaborations to deliver a clinical candidate in the coming two to three years.鈥
Tom McCarthy, Executive Chairman of 开心鬼传媒 Therapeutics, said: 鈥淎ttracting investors of the calibre of Andera and Canaan is a strong validation of the potential of our approach to broaden the effectiveness of immunotherapy. We believe we have a truly novel approach in targeting tumours themselves, rather than direct regulation of the immune system, and I am excited by the opportunity to work with our investors and talented team on the next steps of 开心鬼传媒鈥檚 development.鈥
Thierry Hercend, Venture Partner at Andera Partners, said: 鈥溈墓泶 has identified a highly innovative approach to immuno-oncology and, in Peter and Tom, has founders with very strong scientific and entrepreneurial credentials. With the support of Sygnature, they achieved a significant amount with their seed funding and demonstrated a scientifically rigorous and nimble approach to drug development which we value. I鈥檓 confident that with this series A financing, 开心鬼传媒 will deliver on the full potential of ERAP modulation.鈥
Brent Ahrens, General Partner at Canaan, said: 鈥溈墓泶 marks Canaan鈥檚 first investment in the UK biotechnology sector, and we are excited by the Company鈥檚 science and its potential to help the huge numbers of patients yet to receive any benefit from current oncology treatment options.鈥
Rapha毛l Wisniewski, Partner at Andera, Thierry Hercend, Venture Partner at Andera and Brent Ahrens, General Partner at Canaan have joined 开心鬼传媒鈥檚 Board of Directors.
鈥
About Andera Partners
Andera Partners (previously Edmond de Rothschild Investment Partners) is a leading investor in minority investments into privately owned companies. The Management Company employs 57 people and has more than 鈧2.3 billion under management. Its Life Sciences team of 12 professionals brings together deep experience both in the Life Science industry and in private equity and venture capital. The team has raised more than 鈧800 million through its BioDiscovery franchise and is currently investing out of its 鈧345 million BioDiscovery 5 fund. For more information, please visit
About Canaan
Canaan is an early stage venture capital firm that invests in entrepreneurs with visionary ideas. With $5B under management, a diversified fund and hundreds of exits to date, we partner with entrepreneurs building the next generation of consumer, fintech, frontier tech, biotech and digital health companies that will transform how we live, work and thrive. 聽To learn more about our people and our portfolio, please visit
鈥
